

# Marcus Thuresson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/206431/publications.pdf>

Version: 2024-02-01

66  
papers

4,894  
citations

126907

33  
h-index

102487

66  
g-index

66  
all docs

66  
docs citations

66  
times ranked

6284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	4.6	32
2	Sodium-glucose cotransporter-2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 67-73.	2.4	7
3	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
4	Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015. <i>Primary Care Diabetes</i> , 2021, 15, 262-268.	1.8	9
5	Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 75-85.	4.4	43
6	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. <i>Diabetes Care</i> , 2021, 44, 1211-1218.	8.6	32
7	Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 19-27.	4.4	12
8	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). <i>European Journal of Heart Failure</i> , 2021, 23, 1499-1511.	7.1	80
9	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021, 20, 159.	6.8	15
10	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 27-35.	11.4	215
11	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	4.4	33
12	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1607-1618.	4.4	118
13	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 606-615.	11.4	67
14	Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting. <i>International Journal of COPD</i> , 2020, Volume 15, 235-245.	2.3	17
15	Dapagliflozin vs non-SGLT2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2651-2659.	4.4	10
16	Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study. <i>BMJ Open</i> , 2019, 9, e027199.	1.9	5
17	Impact of Preoperative Symptoms and Revascularized Arterial Segment in Patients With Chronic Limb-Threatening Ischemia. <i>Vascular and Endovascular Surgery</i> , 2019, 53, 365-372.	0.7	1
18	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1136-1145.	4.4	61

#	ARTICLE	IF	CITATIONS
19	How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 968-974.	4.4	66
20	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	8.6	23
21	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of) Tj ETQq1 1 0:784314 6GBT /Ove	1.6	6
22	Comorbidity, disease burden and mortality across age groups in a Swedish primary care asthma population: An epidemiological register study (PACEHR). <i>Respiratory Medicine</i> , 2018, 136, 15-20.	2.9	23
23	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2628-2639.	2.8	370
24	Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2 inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1983-1987.	4.4	65
25	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 344-351.	4.4	164
26	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00036.	2.4	24
27	Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR). <i>Respiratory Research</i> , 2018, 19, 168.	3.6	30
28	SGLT-2 Inhibitors and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2497-2506.	2.8	113
29	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6–10. <i>Diabetes Care</i> , 2018, 41, e106-e108.	8.6	8
30	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6–10. <i>Diabetes Care</i> , 2018, 41, e104-e105.	8.6	5
31	Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 10-17.	4.0	19
32	Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR). <i>European Respiratory Journal</i> , 2018, 52, 1701927.	6.7	22
33	Factors associated with lung cancer in COPD patients. <i>International Journal of COPD</i> , 2018, Volume 13, 1833-1839.	2.3	27
34	Editor's Choice – Effect of More Expedited Carotid Intervention on Recurrent Ischaemic Event Rate: A National Audit. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 467-474.	1.5	6
35	Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). <i>Respiratory Research</i> , 2018, 19, 12.	3.6	71
36	Editor's Choice – Impact of Comorbidity, Medication, and Gender on Amputation Rate Following Revascularisation for Chronic Limb Threatening Ischaemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 681-688.	1.5	38

#	ARTICLE	IF	CITATIONS
37	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 831-841.	4.4	75
38	Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study. <i>Journal of Vascular Surgery</i> , 2017, 66, 507-514.e1.	1.1	59
39	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. <i>Circulation</i> , 2017, 136, 249-259.	1.6	672
40	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 199-208.	2.8	44
41	Dapagliflozin Is Associated With Lower Risk Of Hospitalization For Kidney Disease, Heart Failure And All Cause Death Compared To DPP-4i: CVD-REAL Nordic. <i>Canadian Journal of Diabetes</i> , 2017, 41, S51.	0.8	1
42	Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. <i>Circulation</i> , 2017, 136, 1183-1192.	1.6	128
43	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 709-717.	11.4	285
44	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 42-52.e8.	1.9	75
45	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. <i>Diabetologia</i> , 2016, 59, 1692-1701.	6.3	93
46	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 39-47.	2.8	68
47	Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. <i>Prostate</i> , 2016, 76, 905-916.	2.3	58
48	Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 115.	1.7	45
49	Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting: results from a contemporary nationwide registry study. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 291-298.	4.0	16
50	Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. <i>Journal of Vascular Surgery</i> , 2016, 64, 1009-1017.e3.	1.1	88
51	Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 99-107.	1.2	33
52	Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 172-183.	4.0	88
53	Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. <i>Clinical Drug Investigation</i> , 2016, 36, 225-233.	2.2	12
54	DIAGNOSTIC COLPOSCOPIC ACCURACY BY THE GYNOCULAR AND A STATIONARY COLPOSCOPE. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 181-187.	0.5	10

#	ARTICLE	IF	CITATIONS
55	Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 13-21.	2.7	3
56	Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. <i>European Heart Journal</i> , 2015, 36, 1163-1170.	2.2	604
57	Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. <i>Journal of Hepatology</i> , 2015, 63, 456-461.	3.7	98
58	Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study. <i>Bipolar Disorders</i> , 2015, 17, 76-85.	1.9	54
59	Evaluation of the accuracy in detecting cervical lesions by nurses versus doctors using a stationary colposcope and Gynocular in a low-resource setting. <i>BMJ Open</i> , 2014, 4, e005313.	1.9	26
60	Evaluation of Stationary Colposcope and the Gynocular, by the Swede Score Systematic Colposcopic System in VIA Positive Women: A Crossover Randomized Trial. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 339-345.	2.5	38
61	A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 411-418.	2.5	95
62	Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 20-26.	1.9	98
63	Cardiovascular Events in Subgroups of Patients During Primary Treatment of Hypertension With Candesartan or Losartan. <i>Journal of Clinical Hypertension</i> , 2011, 13, 189-197.	2.0	8
64	Mechanical load and EMG activity in the neck induced by different head-worn equipment and neck postures. <i>International Journal of Industrial Ergonomics</i> , 2005, 35, 13-18.	2.6	50
65	Intra-rater reliability of electromyographic recordings and subjective evaluation of neck muscle fatigue among helicopter pilots. <i>Journal of Electromyography and Kinesiology</i> , 2005, 15, 323-331.	1.7	17
66	Neck muscle activity in helicopter pilots: effect of position and helmet-mounted equipment. <i>Aviation, Space, and Environmental Medicine</i> , 2003, 74, 527-32.	0.5	18